Jove
Visualize
Contact Us

Related Experiment Videos

Oncolytic virus therapy using genetically engineered herpes simplex viruses.

Tomoki Todo1

  • 1Department of Neurosurgery, The University of Tokyo, Tokyo, Japan. toudou-nsu@umin.ac.jp

Frontiers in Bioscience : a Journal and Virtual Library
|November 6, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Induced pluripotent stem cell-derived dendritic cells potentiate the efficacy of interleukin-12-expressing oncolytic HSV-1.

Molecular therapy. Oncology·2026
Same author

Oncolytic Herpes Virus G47∆ Potentiates ADCC-Inducing Molecular Targeted Therapy via Coordinated Activation of Innate and Adaptive Immune Responses.

Molecular cancer therapeutics·2026
Same author

Triple-Mutated HSV-1 Expressing Soluble B7-1 Plus CTLA-4 Blockade Suppresses Lymph Node Metastasis in Tongue Cancer.

Cancer science·2026
Same author

MicroRNA-138 regulation promotes the efficacy of oncolytic herpes virus G47Δ for malignant brain tumor therapy.

Molecular therapy. Oncology·2026
Same author

Multihit Somatic Mosaicism of <i>TP53</i> Pathogenic Variants in a Patient Mimicking Li-Fraumeni Syndrome.

JCO precision oncology·2025
Same author

Epithelial-Mesenchymal Transition and Genetically Driven Early Tumor Seedings in Extraneural Metastasis of Glioblastoma.

Cancer science·2025
Same journal

The CD44 protein family: roles in embryogenesis and tumor progression.

Frontiers in bioscience : a journal and virtual library·2017
Same journal

Four varieties of voltage-gated proton channels.

Frontiers in bioscience : a journal and virtual library·2017
Same journal

Lurie's tubercle-count method to test TB vaccine efficacy in rabbits.

Frontiers in bioscience : a journal and virtual library·2017
Same journal

Optical spectroscopy of breast biopsies and human breast cancer xenografts in nude mice.

Frontiers in bioscience : a journal and virtual library·2017
Same journal

The colostrum-deprived, artificially-reared, neonatal pig as a model animal for studying rotavirus gastroenteritis.

Frontiers in bioscience : a journal and virtual library·2017
Same journal

Action of polypeptide growth factors in colon cancer; development of new therapeutic approaches.

Frontiers in bioscience : a journal and virtual library·2017
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Genetically engineered herpes simplex virus type 1 (HSV-1) shows promise for cancer treatment. A new version, G47delta, demonstrates enhanced immune response and tumor-killing ability, paving the way for clinical trials.

Area of Science:

  • Oncolytic virotherapy
  • Cancer immunotherapy
  • Viral gene therapy

Background:

  • Genetically engineered herpes simplex virus type 1 (HSV-1) exhibits oncolytic activity and can deliver foreign genes.
  • Previous studies with G207 demonstrated the safety of oncolytic HSV-1 in human brain tumors.
  • Therapeutic success relies on viral replication and host antitumor immune responses.

Purpose of the Study:

  • To develop a new-generation oncolytic HSV-1 with enhanced antitumor properties and retained safety.
  • To evaluate the efficacy and safety of G47delta, a modified HSV-1, in preclinical models.
  • To establish a system for creating "armed" oncolytic HSV-1 for enhanced immune stimulation.

Main Methods:

  • Development of G47delta, a triple-mutated HSV-1 derived from G207.

Related Experiment Videos

  • In vitro and in vivo evaluation of G47delta's replication, cytopathic effects, and antitumor efficacy.
  • Creation of an "armed" HSV-1 system using bacterial artificial chromosome and DNA recombinases for transgene insertion.
  • Assessment of G47delta's safety in the brain of HSV-1-sensitive mice.

    • Main Results:

    • G47delta demonstrated superior stimulation of human antitumor immune cells compared to G207.
    • G47delta exhibited enhanced growth properties, higher virus yields, and increased cytopathic effects in vitro.
    • G47delta showed improved antitumor efficacy in both immunocompetent and immunodeficient animal models.
    • G47delta maintained safety in the brain, and expression of immunostimulatory molecules significantly enhanced its antitumor efficacy.

    Conclusions:

    • G47delta represents an advanced oncolytic HSV-1 with enhanced efficacy and safety for cancer treatment.
    • The development of an "armed" HSV-1 generation system allows for rapid and accurate transgene insertion.
    • Oncolytic HSV-1 therapy, particularly with armed variants, holds significant potential as a future cancer treatment modality.